<DOC>
	<DOCNO>NCT00674973</DOCNO>
	<brief_summary>This study design identify biomarkers may predict improvement progression free survival treatment Tarceva , patient advance pancreatic cancer fail one prior regimen standard chemotherapy deem unsuitable chemotherapy . It also assess efficacy safety Tarceva patient population . Patients randomize receive either Tarceva 150mg/day po , placebo po daily . Tumor tissue use biomarker analysis . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Biomarker Identification Trial Tarceva ( Erlotinib ) Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; histologically cytologically document locally advancedunresectable metastatic pancreatic cancer ; measurable disease accord RECIST ; failure least one prior chemotherapy regimen , deem unsuitable chemotherapy ; ECOG performance status 02. local locally advancedresectable pancreatic cancer ; malignancy within last 5 year , except adequately treated cancer situ cervix , basal squamous cell skin cancer ; major surgery within 2 week prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>